Products
Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-828
Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eftilagimod alpha is a large-molecule cancer drug consisting of the four extracellular domains of lymphocyte activation gene-3 (LAG-3) fused to the Fc region of an IgG1(LAG-3Ig). Eftilagimod alpha binds preferentially to a subset of MHC class II molecules that are enriched in lipid rafts and/or composed of stable peptide-MHC II (pMHCII) complexes. On T cells, membrane-anchored LAG-3 is an inhibitory receptor downregulating T-cell receptor (TCR) signaling. Eftilagimod alpha is an MHC class II agonist and therefore a dendritic-cell activator, causing increased antigen presentation to cytotoxic (CD8+) T cells. In the absence of antigen presentation via MHC class II molecules, Eftilagimod alpha reactivates dormant antigen-experienced memory T cells, allowing them to recognize their antigen targets at the tumor site.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-828-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-828-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-828-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-828-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) |
| INN Name | Eftilagimod Alfa |
| Target | MH2 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [LAG3 (lymphocyte activating 3, lymphocyte- activation 3, CD223)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [LAG3 (lymphocyte activating 3, lymphocyte- activation 3, CD223)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Prima BioMed (Sydney NSW Australia) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
